Clinical Trial Update: Safety and Tolerability of Ranibizumab in Mono/Bilateral Wet Age Related Macular Degeneration (w-AMD) Patients in Eyes With BCVA<2/10 and/or 2nd Affected Eye [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update assessing safety and tolerability of ranibizumab in patients with wet age-related macular degeneration, including mono or bilatera…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Wet Age-related Macular Degeneration

Drugs mentioned

• Ranibizumab (ranibizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Wet Age Related Macular Degeneration | Phase 4 | Status: COMPLETED | Results posted: 2019-07-19